ArticleBJUI compass2026
Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.
Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.BJUI compass · 2026Article
- Round up.Indian journal of urology : IJU : journal of the Urological Society of IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Objectives: This study aimed to evaluate the time toxicity of intravesical BCG compared to sequential intravesical gemcitabine and docetaxel (Gem/Doce) for non-muscle-invasive bladder cancer (NMIBC). Patients and Methods: After IRB approval, we retrospectively reviewed patients with NMIBC treated with BCG or Gem/Doce between 2022 and 2025 at our institution. Medical records were used to calculate time for intravesical therapy, office visits, transurethral resection of bladder tumour (TURBT) and emergency department encounters. Continuous variables were compared using the Wilcoxon rank sum test with Hodges-Lehmann estimates. Results: Of 133 patients, 86 received BCG (65%) and 47 Gem/Doce (35%). Patients with BCG were more likely treatment naïve compared to those with Gem/Doce (77% vs 55%, Conclusion: Gem/Doce requires a greater time investment than BCG. As effective NMIBC therapies expand, time toxicity should be considered alongside oncologic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.